Among the clinical and scientific highlights of the American Heart Association Scientific Sessions 2023 (November 11-13) were latest study data on OCEAN(a)-Dose and Lepodisiran, as well as how small apoA isoforms are linked to worse PAD revascularisation outcomes.
Read the reports:
